Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    The Schiehallion Fund

    MCap

    USD1,307m

    Last close

    USD1.29

    ▲ 92.88 (8,270.44%)

    Metals One

    MCap

    —

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

    Biomea Fusion

    MCap

    USD109m

    Last close

    USD1.54

    ▲ 0.20 (14.93%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Bull, Bear & Beyond – Oryzon Genomics: executive interview

Bull, Bear & Beyond – Oryzon Genomics: executive interview

Oryzon Genomics — 1 video in collection

More on this equity

Oryzon Genomics is a Spanish biotechnology company focused on epigenetics. Its two lead assets, vafidemstat (central nervous system, CNS) and iadademstat (oncology), are in the clinical stages of development for various indications. Both are small molecule inhibitors of LSD1, a histone-modifying enzyme that forms part of complexes responsible for the regulation of genes implicated in CNS disorders and cancer.

Listen on your preferred podcast player below:

About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.

< Previous
Next >

You may also be interested in these:

Healthcare

Bull, Bear & Beyond – Medigene: executive interview

Healthcare

Bull, Bear & Beyond – AFT Pharmaceuticals: executive interview